Business
Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™
MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with
About this update from Nuwellis, Inc.
[{"type":"text","content":"MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the recent grant of a new patent from the United States Patent and Trademark Office (USPTO) related to its groundbreaking pediatric continuous renal replacement therapy (CRRT), Vivian™. This patent covers critical advancements that will significantly improve the performance and user experience of Vivian. This is the second of several forthcoming patents for Vivian, underscoring Nuwellis’ commitment to development of novel technology designed to improve treatment options for critically ill children. The patent claims, include self-centering fluid bag hangers and density compensation mechanisms for enhanced accuracy in fluid management. Ease of use is increased with self-sealing access ports for easy configuration of various dialysis modes, streamlining the treatment process. Additionally, reliability is boosted by a temperature-adjusting auto-clamp that ensures secure seals, reducing the risk of leaks and enhancing overall system dependability. \"We are thrilled to announce the issuance of this patent, which represents a significant milestone in the development of our pediatric continuous renal replacement therapy, Vivian,\" said Nestor Jaramillo, President and Chief Executive Officer at Nuwellis. \"These innovations not only reinforce our position as a leader in fluid management solutions but also highlight our dedication to advancing technology that can make a real difference in the lives of thousands of pediatric patients across the U.S. Our focus on increased accuracy, ease of use, and reliability will help ensure that children receiving critical care have access to the best possible treatment options.\" About VivianNuwellis is currently developing Vivian, a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children with limited or no kidney function. Vivian is not yet cleared by the FDA. This development effort was funded in part by a $1.7 million grant from the National Institutes of Health (NIH). The company has partnered with Minneapolis-based research and development firm Koronis Biomedical Technologies Corporation (KBT), the grant recipient, in the design an...